MediWound

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

MediWound reports $5M revenue, advances trials and manufacturing capacity

MediWound's Q1 2024 performance reflects solid revenue from NexoBrid, progress on manufacturing, and strategic advancements in clinical trials and FDA interactions.
While facing challenges in profitability and operational expenses, the company's strengths in innovation, market acceptance, and growth opportunities position it for future success.
With a focus on operational excellence and expansion plans, MediWound remains well-positioned to capitalize on market opportunities and drive sustainable growth.

MediWound reports revenue growth but faces profit challenges in Q2 2024

MediWound's Q2 2024 performance showed revenue growth but faced challenges with decreased gross profit and increased losses. Despite liquidity concerns, the company is capitalizing on opportunities in NexoBrid and EscharEx developments. Analyst interest in capacity expansion and trial funding indicates market potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

MediWound (MDWD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.41 per share. This compares to loss of $0.91 per share a year ago.

MediWound (MDWD) Q2 Earnings and Revenues Beat Estimates

EscharEx ® Phase III study protocol : FDA/EM A-aligned ; p atient enrollment commencing early 2024 ; two key research collaborations with wound industry leaders

MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update

MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg ulcers MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg ulcers

MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study

MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers

MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study

Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time

MediWound to Report Second Quarter 2023 Financial Results

Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement

MediWound Announces Commercial Launch of NexoBrid® in Japan

StealthGas

Yatra Online

Micro-cap stocks, by definition, are stocks of companies that trade at a valuation range of $50 to $300 million. It goes without saying that investing in micro-cap stocks is a high-risk game.

3 Micro-Cap Stocks to Buy for Multibagger Returns

MW005 shown to be safe and well-tolerated Data provide clinical efficacy proof-of-concept based on clearance of target lesions YAVNE, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced positive data from its Phase I/II study to evaluate the safety and efficacy of MW005 in the treatment of low-risk Basal Cell Carcinoma (BCC).

MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

Affirms the clear path forward for the Company's global Phase III study of EscharEx in venous leg ulcers Affirms the clear path forward for the Company's global Phase III study of EscharEx in venous leg ulcers

MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design

YAVNE, Israel, June 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming Healthcare Virtual Conference Part II, organized by Maxim Group LLC and hosted by M-Vest. The conference will take place online from June 20 to June 22, 2023.

MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023

MediWound, a company developing medical solutions for skin and burn conditions, is set to begin US distribution of its burn solution NexoBrid in Q3 2023. With a cash pile of over $57 million, the company will be able to cover operating expenses and then some for the next 2-3 years as they ramp up production. Despite past share price underperformance, I remain cautiously bullish on the company's long term prospects and believe they are worth around double their current valuation.

MediWound: With Expenses Covered, Growth Is Within Reach

MediWound Ltd. (NASDAQ:MDWD ) Q1 2023 Earnings Conference Call May 30, 2023 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors, IR Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice President of Strategy & Corporate Development Conference Call Participants Josh Jennings - TD Cowen Francois Brisebois - Oppenheimer Michael Okunewitch - Maxim Group Swayampakula Ramakanth - H.C.

MediWound Ltd. (MDWD) Q1 2023 Earnings Call Transcript

MediWound (MDWD) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.84 per share a year ago.

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

On track to initiate EscharEx ® Phase III study in fourth quarter 2023 NexoBrid ® U.S. launch expected in early third quarter 2023 Cash of over $57 million; Operating cash runway through profitability

MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update

Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time

MediWound to Report First Quarter 2023 Financial Results

Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension

MediWound Announces an Additional $10 Million Award from BARDA

Data to be highlighted in oral and poster presentations YAVNE, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic solutions for tissue repair, today announced the Company will present updated clinical data from the three EscharEx® Phase 2 trials at the 2023 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society taking place in National Harbor, Maryland on April 26-30, 2023.

MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023

MediWound Ltd. (NASDAQ:MDWD ) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors, IR Ofer Gonen - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Josh Jennings - TD Cowen Francois Brisebois - Oppenheimer Swayampakula Ramakanth - H.C.

MediWound Ltd. (MDWD) Q4 2022 Earnings Call Transcript

MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update

YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound's Chief Financial Officer for the past four years. Mr. Gur-Lavie will remain with the Company through July 31, 2023 to ensure an orderly transition.

MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Appoints Barry Wolfenson, as Executive Vice President of Strategy and Corporate Development

MediWound Expands its Global Leadership Team to Help Drive Company's Future Growth

Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time

MediWound to Report Fourth Quarter and Year-End 2022 Financial Results

YAVNE, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced management will present at two upcoming investor conferences in March. Details for each is as follows:

MediWound to Present Corporate Highlights at Upcoming Investor Conferences

YAVNE, Israel, Feb. 07, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the closing of its previously announced registered direct offering. The gross proceeds to the Company from the offering were $27.5 million, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering primarily for the acceleration of the development of EscharEx®, establishing a U.S. commercial presence, supporting business development activities, and for general corporate purposes. The Company may also use a portion of the net proceeds to in-license, invest in or acquire businesses, technologies, products or assets that it believes are complementary to its own, although it has no current plans, commitments or agreements with respect to any acquisitions or in-licenses at this time.

News for MediWound Stock (MDWD)